Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation daily Stock Chart
Celgene Corporation
IndexS&P 500 P/E42.28 EPS (ttm)3.22 Insider Own0.20% Shs Outstand794.05M Perf Week-1.83%
Market Cap107.96B Forward P/E15.24 EPS next Y8.92 Insider Trans-15.26% Shs Float780.42M Perf Month-5.74%
Income2.60B PEG1.95 EPS next Q1.88 Inst Own81.60% Short Float1.31% Perf Quarter-1.29%
Sales12.19B P/S8.86 EPS this Y28.10% Inst Trans-3.33% Short Ratio2.75 Perf Half Y11.21%
Book/sh10.82 P/B12.57 EPS next Y21.77% ROA9.10% Target Price154.22 Perf Year35.93%
Cash/sh12.77 P/C10.65 EPS next 5Y21.65% ROE36.70% 52W Range96.93 - 147.17 Perf YTD17.46%
Dividend- P/FCF25.78 EPS past 5Y11.80% ROI11.70% 52W High-7.62% Beta1.88
Dividend %- Quick Ratio3.90 Sales past 5Y18.30% Gross Margin96.30% 52W Low40.27% ATR2.44
Employees7132 Current Ratio4.10 Sales Q/Q18.70% Oper. Margin27.60% RSI (14)40.06 Volatility1.85% 1.69%
OptionableYes Debt/Eq1.69 EPS Q/Q75.10% Profit Margin21.30% Rel Volume1.33 Prev Close137.17
ShortableYes LT Debt/Eq1.63 EarningsOct 26 BMO Payout0.00% Avg Volume3.73M Price135.96
Recom1.70 SMA20-3.98% SMA50-1.50% SMA2006.95% Volume5,700,001 Change-0.88%
Oct-17-17Initiated Bernstein Outperform
Oct-05-17Downgrade Morgan Stanley Equal-Weight → Underweight
Sep-15-17Reiterated Mizuho Buy $134 → $158
Sep-15-17Initiated RBC Capital Mkts Top Pick $176
Jul-31-17Upgrade Argus Hold → Buy
Jul-28-17Resumed Stifel Buy $155
Jul-11-17Resumed Jefferies Buy
Jun-30-17Downgrade BTIG Research Buy → Neutral
Jun-16-17Upgrade Leerink Partners Mkt Perform → Outperform
Jun-01-17Reiterated Mizuho Buy $130 → $134
May-05-17Downgrade Argus Buy → Hold
Mar-09-17Initiated UBS Buy $140
Nov-09-16Downgrade Standpoint Research Buy → Hold
Nov-08-16Initiated Mizuho Buy $130
Jul-15-16Initiated Stifel Buy $138
Apr-29-16Reiterated Sun Trust Rbsn Humphrey Buy $145 → $147
Feb-25-16Initiated Citigroup Buy $130
Jan-20-16Initiated Credit Suisse Outperform
Jan-14-16Initiated Standpoint Research Buy $130
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $145
Oct-20-17 12:33AM  S&P 500 Futures Jump After Senate OKs Budget Resolution Paving Way For Tax Cuts Investor's Business Daily
Oct-19-17 05:59PM  Final Trades: HAIN, CELG & PHM CNBC Videos
05:49PM  Drug That Celgene Bought For $710 Million Fails Forbes
05:26PM  Celgene Falls After Scrapping Crohn's Disease Drug Trials Investor's Business Daily
05:13PM  Celgene shares drop after Crohn's disease drug trials halted MarketWatch
05:10PM  Celgene reopens, shares plunge CNBC Videos
04:44PM  Celgene abandons Crohn's disease drug trials Reuters
04:35PM  Celgene won't initiate phase 3 trial for Crohn's disease drug CNBC
04:34PM  Celgene discontinues trial of Crohn's disease drug CNBC Videos
04:30PM  Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program Business Wire
09:46AM  Celgene: Look Beyond Any Short-Term Weakness
09:08AM  The Zacks Analyst Blog Highlights: IBM, Celgene, Procter & Gamble, Valero and Sprint Zacks
07:30AM  Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 7th Joint ECTRIMS ACTRIMS Meeting Business Wire
Oct-18-17 03:13PM  Top Stock Reports for IBM, Celgene and Procter & Gamble Zacks
09:55AM  Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals Zacks
06:00AM  Biogen Could Rise 20% on Healthy Outlook Investopedia
Oct-17-17 04:47PM  Celgene Blood Cancer Treatment: Just The Tip Of Its Disruptive Science? Investor's Business Daily
04:25PM  Top 3 Healthcare Stocks for 2017 Investopedia
03:55PM  Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks Zacks
10:04AM  Immune Design's Sarcoma Candidate to Enter Phase III in 2018 Zacks
08:57AM  The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene Zacks
Oct-16-17 06:07PM  Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada Zacks
05:43PM  Bayer to Sell Select Business Lines to Close Monsanto Buyout Zacks
09:49AM  ETFs with exposure to Celgene Corp. : October 16, 2017 Capital Cube
08:36AM  Celgene Corp. breached its 50 day moving average in a Bearish Manner : CELG-US : October 16, 2017 Capital Cube
08:10AM  Today's Research Reports on Stocks to Watch: Celgene Corporation and Valeant Pharmaceuticals ACCESSWIRE
08:01AM  6 Top Biotech Companies In Innovation Earn Recognition In New Awards Investor's Business Daily
08:01AM  Results from Phase 2 Studies of Oral Ozanimod in Crohns Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017 Business Wire
Oct-15-17 11:05PM  [$$] Nimbus Therapeutics Strikes Immunology Deal With Celgene The Wall Street Journal
Oct-13-17 03:01PM  Valeant Reports Positive Results on Psoriasis Drug Siliq Zacks
Oct-12-17 06:56PM  Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017 Zacks
02:35PM  Top 5 Biotech Stocks for 2017 Investopedia
06:04AM  7 Essential Rules for Investing in Biotech Stocks Motley Fool
06:00AM  Celgene, Biogen Are Poised to Break Out: A Technical View Investopedia
Oct-10-17 04:50PM  Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel Zacks
03:15PM  MannKind Tripled In The Past 3 Weeks; Vindicating Nate Pile Forbes
11:00AM  Amgen Label Expansion Application for Prolia Accepted by FDA Zacks
09:45AM  Strategic Research Analysis ­ Positioning to Benefit on  Abbott, Rite Aid, Kroger, Celgene, Twitter, and NIKE ­ Effects of Key Drivers of Growth and Emerging Market Trends GlobeNewswire
07:37AM  Better Buy: Biogen Inc. vs. Celgene Motley Fool
06:04AM  3 Stocks at 52-Week Highs Still Worth Buying Motley Fool
06:02AM  $50,000 Per Year in Prescription Drugs? You Likely Know Someone Who Used at Least That Much Motley Fool
Oct-09-17 10:20AM  Forget Teva (TEVA), Buy These 5 Drug Stocks Instead Zacks
08:02AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
07:41AM  Navient: The S&P 500s Worst Performer on October 5 Market Realist
Oct-08-17 10:48AM  Roundtable: 1 Stock Retirees Should Consider Motley Fool
Oct-07-17 10:34AM  Better Buy: Celgene Corporation vs. Bristol-Myers Squibb Motley Fool
10:29AM  This Dirt-Cheap Biotech Stock Is a Bargain to Buy Motley Fool
Oct-06-17 07:34PM  Cramer Remix: Dont ignore the oldest rule in the game wh... CNBC Videos
06:59PM  Cramer Remix: Dont ignore the oldest rule in the game when it comes to Celgene CNBC
09:37AM  No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock InvestorPlace
07:18AM  Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now? Motley Fool
Oct-05-17 09:00PM  Should You Sell Celgene Stock Following an Analyst Downgrade? Motley Fool
05:00PM  Big biotech trades: 5 plays CNBC Videos
02:32PM  As Celgene Outperforms, Are Challenges To Its Pipeline Being Overlooked? Benzinga
01:29PM  Biotech: Buy Biogen, Sell Celgene
01:06PM  Celgene Is Not a Sell, Jim Cramer Rebuts Analysts' Call
11:59AM  Celgene and Biogen Analyst Moves Are 'Useless,' Jim Cramer Says
09:55AM  Cramer's Stop Trading: Celgene is not a sell CNBC Videos
08:16AM  Morning Movers: Constellation Brands Jumps, Biogen Bounces, Celgene Slips
08:00AM  Which Stocks May Outperform in the Next Market Crash Investopedia
06:03AM  3 Big Pharma Stocks Set to Succeed Motley Fool
Oct-04-17 09:11AM  Amgen Enters Into an Immuno-Oncology Partnership With CytomX Zacks
Oct-03-17 10:42AM  Why bluebird bio, Inc. Stock Gained 10% in September Motley Fool
09:30AM  3 Top-Ranked Big Biotech Stocks to Buy Now Zacks
07:42AM  Nimbus Therapeutics Reaches Summit In Deal With Celgene Forbes
Oct-02-17 11:00PM  [$$] Stock market winners of 2008's crash had one thing in common Financial Times
04:10PM  Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing Investor's Business Daily
08:10AM  Today's Research Reports on Stocks to Watch: Celgene Corporation and Acceleron Pharma ACCESSWIRE
07:30AM  Celgene Corporation to Announce Third Quarter 2017 Results on October 26, 2017; Will Host an Investor Webcast Event from the MSParis20177th Joint ECTRIMS ACTRIMS Meeting on October 28, 2017 Business Wire
01:00AM  Who Wants Tax Reform Less?; Trend: Buy if Up -- Jim Cramer's Top Thoughts
Sep-29-17 09:07PM  All You Need To Know About Celgene Corporations (CELG) Risks Simply Wall St.
11:34AM  1 Great Biotech Stock You Have Never Heard Of Motley Fool
11:09AM  Big Caps Lose Their Lead, But A Few Beat The Trend Investor's Business Daily
05:50AM  [$$] Celgene Invests in Acceleron, BeiGene
Sep-28-17 04:57PM  Bluebird Hits High On Bullish Report Highlighting Blood Drugs Investor's Business Daily
Sep-27-17 10:25AM  Short Sellers Hike Bets in Major Biotechs 24/7 Wall St.
08:33AM  5 Drugs That Could Make Celgene the Best Biotech Stock of the Next Decade Motley Fool
08:03AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
03:00AM  Stocks Showing Market Leadership: Sarepta Therapeutics Earns 91 RS Rating Investor's Business Daily
03:00AM  Stocks Flashing Renewed Technical Strength: Innoviva Investor's Business Daily
03:00AM  Acceleron Pharma Reaches 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
Sep-26-17 08:02AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
07:17AM  3 Bargain Biotech Stocks You Can Buy Today Motley Fool
03:00AM  Acorda Therapeutics Getting Closer To Key Technical Measure Investor's Business Daily
Sep-22-17 04:00PM  Oddly, Juno Therapeutics Is Jumping 11.3% Today Motley Fool
03:11PM  Juno Tenders $250M Follow-on Public Offering of Common Stock Zacks
07:43AM  3 Big Biotech Stocks to Buy This Fall Motley Fool
06:04AM  Better Buy: Celgene Corporation vs. Merck & Co., Inc. Motley Fool
Sep-21-17 08:04AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
Sep-20-17 04:47PM  Top Research Reports for Northrop Grumman, BNY Mellon & Celgene Zacks
08:25AM  3 Stocks That Put Coca-Cola's Returns to Shame Motley Fool
08:04AM  See what the IHS Markit Score report has to say about Celgene Corp. Markit
Sep-19-17 07:31AM  These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys? Motley Fool
07:09AM  Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade InvestorPlace
07:01AM  Apple Leads 7 Top Stocks Holding In Buy Range Investor's Business Daily
Sep-18-17 05:59PM  Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA Zacks
02:19PM  What Analysts Recommend for Novartis in September 2017 Market Realist
02:16PM  RBC Capital's Marc Harris breaks down his best biotech pi... CNBC Videos
11:35AM  Gilead Sciences: Is The Kite Deal Too Little, Too Late?
Sep-17-17 09:18AM  Don't Make This Huge Mistake With Celgene Motley Fool
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. and Nimbus Therapeutics. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Curran TerrieSee remarksSep 25Sale143.891,727248,4983,925Sep 26 04:29 PM
KAPLAN GILLADirectorSep 12Option Exercise33.889,250313,39085,551Sep 14 04:35 PM
KAPLAN GILLADirectorSep 12Sale141.569,2501,309,43076,301Sep 14 04:35 PM
CASEY MICHAEL DDirectorSep 05Sale139.039,2501,286,0280Sep 06 06:53 PM
MARIO ERNESTDirectorAug 10Sale130.5218,5062,415,40369,424Aug 14 04:53 PM
KAPLAN GILLADirectorAug 02Sale134.527,5001,008,90076,301Aug 03 04:45 PM
Curran TerrieSee remarksAug 01Option Exercise0.001,50006,210Aug 02 04:38 PM
KELLOGG PETER NSee RemarksAug 01Option Exercise0.0060,000070,833Aug 02 04:37 PM
Smith Scott AndrewSee RemarksJul 28Option Exercise0.005,000045,415Aug 01 05:34 PM
PEHL MICHAEL F.See remarksJul 28Option Exercise0.002,50003,488Aug 01 04:56 PM
HUGIN ROBERT Jsee remarksJul 28Option Exercise0.0044,50001,021,159Aug 01 04:52 PM
Alles Mark JSee RemarksJul 28Option Exercise0.004,2000175,120Aug 01 04:48 PM
MARIO ERNESTDirectorJul 01Option Exercise0.00734087,930Jul 05 07:33 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00734024,361Jul 05 07:33 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073400Jul 05 07:31 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00734083,801Jul 05 07:32 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073400Jul 05 07:30 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00734023,880Jul 05 07:31 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00734012,066Jul 05 07:29 PM
LOUGHLIN JAMES JDirectorJun 26Option Exercise29.4318,500544,36332,877Jun 27 04:39 PM
LOUGHLIN JAMES JDirectorJun 26Sale133.5718,5002,471,04523,627Jun 27 04:39 PM
Friedman Michael ADirectorJun 22Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Option Exercise29.49178,7205,271,0061,033,909Jun 23 04:02 PM
HUGIN ROBERT Jsee remarksJun 22Sale134.14175,97023,604,616973,909Jun 23 04:02 PM
Friedman Michael ADirectorJun 22Sale135.005,000675,0000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Option Exercise33.889,250313,3909,250Jun 23 04:05 PM
Friedman Michael ADirectorJun 21Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 21Sale130.005,000650,0000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Sale133.059,2501,230,7130Jun 23 04:05 PM
Friedman Michael ADirectorJun 19Option Exercise59.065,000295,3000Jun 20 04:07 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333083,067Jun 20 04:08 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00333087,196Jun 20 04:09 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00333023,627Jun 20 04:08 PM
VESSEY RUPERTSee remarksJun 15Option Exercise104.164,007417,3584,785Jun 16 04:11 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375086,863Jun 16 04:11 PM
KAPLAN GILLADirectorJun 15Option Exercise0.00375082,734Jun 16 04:09 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.00375023,294Jun 16 04:10 PM
Haller Julia ADirectorJun 15Option Exercise0.003750575Jun 16 04:09 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 16 04:08 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.003750375Jun 16 04:06 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 16 04:06 PM
VESSEY RUPERTSee remarksJun 15Sale120.184,785575,0380Jun 16 04:11 PM
KAPLAN GILLADirectorJun 01Option Exercise28.979,250267,92682,359Jun 02 04:11 PM
CASEY MICHAEL DDirectorMay 30Option Exercise28.979,250267,926100,612May 31 04:10 PM
LOUGHLIN JAMES JDirectorMay 01Option Exercise28.969,250267,88032,169May 02 04:20 PM
LOUGHLIN JAMES JDirectorMay 01Sale124.009,2501,147,00022,919May 02 04:20 PM
HUGIN ROBERT Jsee remarksApr 10Option Exercise29.0260,0001,741,200973,909Apr 12 04:24 PM
KAPLAN GILLADirectorMar 30Sale123.8314,0331,737,70673,109Mar 31 05:31 PM
KAPLAN GILLADirectorMar 03Option Exercise25.587,500191,81387,142Mar 07 04:37 PM
VESSEY RUPERTSee remarksMar 01Sale124.424,000497,672778Mar 02 04:04 PM
CASEY MICHAEL DDirectorFeb 27Option Exercise25.587,500191,8507,500Mar 01 04:15 PM
CASEY MICHAEL DDirectorFeb 27Sale121.557,500911,6250Mar 01 04:15 PM
MARIO ERNESTDirectorFeb 27Sale121.2412,0001,454,88057,424Aug 31 04:03 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62306,773Feb 06 04:14 PM
Celgene Switzerland LLC10% OwnerFeb 01Buy16.00625,00010,000,0003,456,463Feb 01 04:18 PM
HUGIN ROBERT Jsee remarksJan 05Option Exercise27.4322,708622,767913,909Jan 09 04:11 PM
Smith Scott AndrewSee RemarksDec 23Option Exercise0.006,400039,875Dec 27 04:17 PM
PEHL MICHAEL F.See remarksDec 02Option Exercise0.001,88001,880Dec 06 04:05 PM
Smith Scott AndrewSee RemarksDec 02Option Exercise0.003,750035,419Dec 06 04:05 PM
FOUSE JACQUALYN Asee remarksDec 02Option Exercise0.005,000084,392Dec 06 04:04 PM
Alles Mark JSee RemarksDec 02Option Exercise0.006,5600166,134Dec 06 04:03 PM
VESSEY RUPERTSee remarksNov 22Sale123.182,500307,9501,150Nov 30 04:15 PM
PEHL MICHAEL F.See remarksNov 10Option Exercise68.3920,4241,396,77022,052Nov 15 04:22 PM
PEHL MICHAEL F.See remarksNov 10Sale121.0422,0522,669,1490Nov 15 04:22 PM
Friedman Michael ADirectorNov 09Option Exercise31.8018,600591,48018,600Nov 10 04:14 PM
HUGIN ROBERT Jsee remarksNov 09Sale120.00100,00012,000,000922,201Nov 14 05:47 PM
Friedman Michael ADirectorNov 09Sale116.1018,6002,159,4600Nov 10 04:14 PM
CELGENE CORP /DE/10% OwnerOct 24Buy14.00800,15011,202,1004,834,980Oct 26 04:15 PM